Business & markets
Pfizer Raises Full-Year Outlook and Appoints New Executive
Pfizer's third-quarter adjusted earnings per share and revenue both exceeded market expectations, and it raised its full-year revenue and adjusted profit guidance. The company said growth from newly launched and acquired products offset weakness in its COVID-19 business, while announcing that Cecile Gagan will become chief financial officer effective this month.
Pfizer's third-quarter revenue was $16.58 billion, above the $15.87 billion expected in an LSEG survey; adjusted earnings per share were 87 cents, above expectations of 73 cents. The company's revenue was roughly flat from the same period last year, with lower COVID-19 revenue causing an operational decline of $57 million and foreign exchange creating a $15 million negative impact.
Pfizer raised its full-year revenue outlook from $60.5 billion to $62.5 billion to $62 billion to $64 billion. The lower end of the new range is roughly in line with or slightly below 2025 revenue of $62.6 billion. The company also expects full-year adjusted earnings per share of $2.95 to $3.05, up from previous guidance of $2.80 to $3.
The company said the improved outlook was mainly driven by growing demand for newly launched and acquired products, with strong sales of key products such as Eliquis and Padcev. Chief Executive Albert Bourla said revenue from COVID-19 products this quarter and this year was “very low,” but that instead demonstrates the company has reduced its dependence on that business; full-year COVID-19 product revenue is still expected to be about $4 billion, with most vaccine sales expected to occur during the fourth-quarter vaccination season.
Third-quarter results included a one-time charge of $650 million, with a negative impact of 10 cents per share, related to the company's licensing cooperation agreement with Chinese innovative drugmaker Innovent Biologics.
On the personnel front, Cecile Gagan became chief financial officer effective this month. She has held multiple finance leadership roles at Pfizer over the past 20 years and had served as interim CFO since August; former CFO Dave Denton departed and joined Nike.
In the post-pandemic era, Pfizer is pursuing growth through strategic acquisitions, new cancer drugs, and its acquisition of Metsera to establish a position in weight-loss treatments. In August, the company expanded its multiyear cost-reduction program, targeting about $9.7 billion in net savings by 2029.